Pharmacological treatment of pediatric Gaucher disease.

Abstract:

INTRODUCTION:Gaucher disease (GD) is an autosomal recessive disorder resulting from the deficiency of the lysosomal enzyme glucocerebrosidase (b-glucosidase), associated with varying degrees of visceral, bone and central nervous system pathology, leading to wide phenotypic diversity. Response to therapy and clinical outcomes are very different between the three clinical subtypes - non-neuronopathic, acute neuronopathic, and chronic neuronopathic forms; hence a definitive clinical diagnosis is essential. The availability of two therapeutic options, i.e. enzyme replacement and substrate reduction, has transformed the natural course of the disease. As pre-treatment disease severity clearly impacts results of therapy, early diagnosis and initiation of treatment especially in the pediatric population are keys to achieving an optimal outcome. Areas covered: We reviewed the literature concerning the treatment of GD focusing on pediatric presentations, various pharmacological treatment options and recommendations for management goals. A PubMed literature search was performed for relevant publications between 1991 and September 2018. Expert commentary: The approval of enzyme replacement therapy (ERT) for GD in the pediatric age group has significantly altered the course of the disease, especially for non-neuronopathic and chronic neuronopathic forms, as ERT does not cross the blood-brain barrier. Early diagnosis, regular follow-up and early initiation of treatment can thus prevent some irreversible complications and improve patient quality of life.

authors

Gupta P,Pastores G

doi

10.1080/17512433.2018.1549486

subject

Has Abstract

pub_date

2018-12-01 00:00:00

pages

1183-1194

issue

12

eissn

1751-2433

issn

1751-2441

journal_volume

11

pub_type

杂志文章,评审
  • Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis.

    abstract::Introduction: Primary endpoints and inclusion/exclusion criteria of biologics and small oral molecules for psoriasis treatment have been evolving due to a better understanding of the pathogenesis and potential risks.Areas covered: We analyzed the designs of key phase 3 pivotal trials of all biologics and small oral mo...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2020.1743175

    authors: Hsu SH,Tsai TF

    更新日期:2020-03-01 00:00:00

  • Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.

    abstract::Alzheimer's disease is the most common cause of dementia and is becoming a global health concern. Despite a well-established understanding of the molecular mechanism involved in its pathogenesis, and millions of dollars of investment in drug discovery and clinical trials, no single molecule has yet been approved for i...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2013.811237

    authors: Léger GC,Massoud F

    更新日期:2013-07-01 00:00:00

  • Exploring the neuroregenerative potential of tacrolimus.

    abstract::Introduction: The clinical use of tacrolimus is characterized by many side effects which include neurotoxicity. In contrast, tacrolimus has also shown to have neuroregenerative properties. On a molecular level, the mechanisms of action could provide us more insight into understanding the neurobiological effects. The a...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2019.1675507

    authors: Saffari TM,Bedar M,Zuidam JM,Shin AY,Baan CC,Hesselink DA,Hundepool CA

    更新日期:2019-11-01 00:00:00

  • Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.

    abstract::After the introduction of anti-tumor necrosis factor (anti-TNF) agents, the clinical outcome of patients with Inflammatory Bowel Disease (IBD) has improved significantly. However, use of anti-TNF therapy is complicated by loss of response. In order to maintain remission, adequate serum levels are required. Hence, ther...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2016.1133288

    authors: Strik AS,Bots SJ,D'Haens G,Löwenberg M

    更新日期:2016-01-01 00:00:00

  • Omega-3 polyunsaturated fatty acids for cardiovascular diseases: present, past and future.

    abstract:INTRODUCTION:Large-scale epidemiological studies on Greenlandic, Canadian and Alaskan Eskimos have examined the health benefits of omega-3 fatty acids consumed as part of the diet, and found statistically significant relative reduction in cardiovascular risk in people consuming omega-3 fatty acids. Areas covered: This ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1333902

    authors: Watanabe Y,Tatsuno I

    更新日期:2017-08-01 00:00:00

  • The role of xenobiotic-metabolizing enzymes in the placenta: a growing research field.

    abstract::Introduction: The placenta is a temporary and unique organ that allows for the physical connection between a mother and fetus; this organ regulates the transport of gases and nutrients mediating the elimination of waste products contained in the fetal circulation. The placenta performs metabolic and excretion function...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2020.1733412

    authors: Blanco-Castañeda R,Galaviz-Hernández C,Souto PCS,Lima VV,Giachini FR,Escudero C,Damiano AE,Barragán-Zúñiga LJ,Martínez-Aguilar G,Sosa-Macías M

    更新日期:2020-03-01 00:00:00

  • Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits.

    abstract::Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are effective and widely used antihypertensive drugs. Exposure to these agents is known to be harmful to the fetus in the second and third trimesters of pregnancy. Concerns have also been raised about the risk of congenital malfo...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2015.1005074

    authors: Pucci M,Sarween N,Knox E,Lipkin G,Martin U

    更新日期:2015-03-01 00:00:00

  • Clinical pharmacology of old age.

    abstract::Introduction: With the majority of elderly persons consuming multiple drugs, inappropriate drug use is a major issue in geriatric medicine. Areas covered: We reviewed PubMed, Embase, and Cochrane from inception to 1 May 2019 for potentially inappropriate use of medications, polypharmacy, and age-dependent changes in p...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2019.1632188

    authors: Koren G,Nordon G,Radinsky K,Shalev V

    更新日期:2019-08-01 00:00:00

  • Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy.

    abstract::Magnetic nanoparticles (MNPs) represent a promising nanomaterial for the targeted therapy and imaging of malignant brain tumors. Conjugation of peptides or antibodies to the surface of MNPs allows direct targeting of the tumor cell surface and potential disruption of active signaling pathways present in tumor cells. D...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.12.1

    authors: Wankhede M,Bouras A,Kaluzova M,Hadjipanayis CG

    更新日期:2012-03-01 00:00:00

  • Is single versus combination therapy problematic in the treatment of cutaneous melanoma?

    abstract::Introduction: The development of immunotherapies and targeted therapies has changed the treatment approach in resectable, nonresectable, and metastatic melanoma. Because of their different pharmacological profiles, immunotherapies and/or targeted therapies have been studied in various combinations.Areas covered: We re...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1080/17512433.2019.1650641

    authors: Krattinger R,Ramelyte E,Dornbierer J,Dummer R

    更新日期:2020-03-19 00:00:00

  • JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.

    abstract::Introduction: Rheumatoid arthritis (RA) is a chronic progressive autoimmune disease characterized by synovitis as well as symmetric and destructive arthropathy. Although several disease modified antirheumatic-drugs (DMARDs) have widely used in clinical practice, certain patients are nonresponsive to or cannot take suc...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2019.1615443

    authors: Qiu Q,Feng Q,Tan X,Guo M

    更新日期:2019-06-01 00:00:00

  • Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review.

    abstract::Ziprasidone, a benzisothiazolyl piperazine derivative of tiospirone, is a second-generation antipsychotic with high-affinity antagonism for 5-hydroxytryptophan (5HT)(2A), 5HT(2C), 5HT(1D) and D(2) receptors, pre- and post-synaptic agonism for 5HT(1A) receptors, and inhibition of reuptake for serotonin and norepinephri...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.10.139

    authors: Sacchetti E,Galluzzo A,Valsecchi P

    更新日期:2011-03-01 00:00:00

  • Tedizolid (torezolid) for the treatment of complicated skin and skin structure infections.

    abstract:INTRODUCTION:Acute bacterial skin and skin structure infections (ABSSSI) are among the most frequent infectious diseases. Recently, several new antibiotics with activity against MRSA have been approved. Tedizolid, a second-generation oxazolidinone approved for ABSSSI offers theoretical advantages over first-generation ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2020.1774362

    authors: Carena AA,Stryjewski ME

    更新日期:2020-06-01 00:00:00

  • Pegloticase and the patient with treatment-failure gout.

    abstract::Gout is an inflammatory arthritis characterized by sudden, painful inflammation. Gout can affect any joint in an asymmetric distribution. Gouty attacks may be isolated or can be followed by years of recurrent flares. Over time, elevated serum urate levels and tophaceous deposits can lead to deformity and disability fr...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/ecp.12.48

    authors: Dave AJ,Kelly VM,Krishnan E

    更新日期:2012-09-01 00:00:00

  • Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles.

    abstract:INTRODUCTION:The Pharmacokinetics/pharmacodynamics (PK/PD) relationships with cytotoxics are usually based on a steepening concentration-effect relationship; the greater the drug amount, the greater the effect. The Maximum Tolerated Dose paradigm, finding the balance between efficacy, while keeping toxicities at their ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1477586

    authors: Rodallec A,Fanciullino R,Lacarelle B,Ciccolini J

    更新日期:2018-06-01 00:00:00

  • Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives.

    abstract::Contraceptive management in women with epilepsy is critical owing to the potential maternal and fetal risks if contraception or seizure management fails. This article briefly describes the pharmacokinetic interactions between antiepileptic drugs (AEDs) and hormonal contraceptives and the rational strategies that may o...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/ecp.10.3

    authors: Reddy DS

    更新日期:2010-03-01 00:00:00

  • Dapsone-associated fixed drug eruption.

    abstract:INTRODUCTION:Dapsone is a sulfone drug used to treat infectious conditions and also numerous dermatologic diseases. Fixed drug eruption is a distinctive adverse cutaneous reaction associated with the initial administration and subsequent delivery of a specific agent. Areas covered: The authors preformed a literature se...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1322508

    authors: Garcia D,Cohen PR

    更新日期:2017-07-01 00:00:00

  • Anti-inflammatory strategies in the treatment of schizophrenia.

    abstract::Schizophrenia is a major mental illness with a lifetime prevalence of about 1%. Antipsychotic drugs, with a primary mechanism of action that involves dopamine receptor blockade, are the mainstay in the treatment of the disorder. However, despite optimum antipsychotic treatment, few patients return to pre-morbid levels...

    journal_title:Expert review of clinical pharmacology

    pub_type: 社论

    doi:10.1586/17512433.2016.1095086

    authors: Andrade C

    更新日期:2016-01-01 00:00:00

  • Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.

    abstract:INTRODUCTION:Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin. Despite the known clinical efficacy in relapsed/refractory acute myeloid leukemia (AML), GO was withdrawn from the market in 2010 due to increased e...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1478725

    authors: Baron J,Wang ES

    更新日期:2018-06-01 00:00:00

  • PD-1/PD-L1 pathway inhibitors in advanced prostate cancer.

    abstract:INTRODUCTION:Pharmacological inhibition of immune checkpoint receptors or their ligands represents a transformative breakthrough in the management of multiple cancers. However, immune checkpoint inhibitors have yet to be FDA-approved for the management of metastatic prostate cancer (PCa), the commonest non-cutaneous ma...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1464388

    authors: Isaacsson Velho P,Antonarakis ES

    更新日期:2018-05-01 00:00:00

  • Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.

    abstract::Naltrexone-bupropion is a recently approved drug combination for chronic weight management. In this article, we discuss the rationale for its use as a combination followed by a comprehensive review of safety and efficacy data from major preclinical, phase II and III clinical trials. ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2016.1100072

    authors: Ali KF,Shukla AP,Aronne LJ

    更新日期:2016-01-01 00:00:00

  • Upcoming drugs for the treatment of preeclampsia in pregnant women.

    abstract::Preeclampsia is a pregnancy-specific multisystem disorder, complicating 2 - 8% of pregnancies, and represents a leading cause of maternal and perinatal morbidity and mortality. Recent investigations have elucidated the understanding of its underlying pathogenic mechanisms. However, despite these advances, therapeutic ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/17512433.2014.944501

    authors: Ornaghi S,Paidas MJ

    更新日期:2014-09-01 00:00:00

  • Novel pharmaceuticals in the management of postoperative pain.

    abstract::Novel pharmaceutical advances in postoperative pain management include both non-opioid adjuvants as well as opioid analgesics. Optimizing postoperative analgesics includes improving onset of action, matching duration of analgesia to the setting of use, and minimizing adverse events. To improve on the current standard ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 社论

    doi:10.1586/17512433.2015.1072465

    authors: Palmer P

    更新日期:2015-01-01 00:00:00

  • Treating malaria in pregnancy in developing countries: priorities in clinical research and drug development.

    abstract::Reducing the burden of falciparum malaria in pregnancy is an urgent international public health priority but one that involves considerable challenges. The rapidly declining effectiveness of agents known to be safe in pregnancy, and the limited efficacy, safety and pharmacokinetic data available for many other antimal...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/17512433.1.1.61

    authors: Vallely A,McCarthy J,Changalucha J,Vallely L,Chandramohan D

    更新日期:2008-01-01 00:00:00

  • Sex and gender influences on pharmacological response: an overview.

    abstract::Research on the specific effects of sex and gender on pharmacokinetics and pharmacodynamics, as well as safety profile tolerability and drug efficacy, of medications remain meager because female animals and women have only recently been included in the pharmacological domain. To date, the influence of sex and gender o...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2014.922866

    authors: Franconi F,Campesi I

    更新日期:2014-07-01 00:00:00

  • Clinical pharmacology in HIV cure research - what impact have we seen?

    abstract::Introduction: Combined antiretroviral therapy (cART) has transformed an inexorably fatal disease into a chronic pathology, shifting the focus of research from the control of viral replication to the possibility of HIV cure. Areas covered: The present review assesses the principal pharmacological strategies that have b...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2019.1561272

    authors: Giacomelli A,de Rose S,Rusconi S

    更新日期:2019-01-01 00:00:00

  • Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection.

    abstract:INTRODUCTION:Patients with moderate to severe COVID-19 infection require specific drugs to prevent the morbidity and mortality. Hydroxychloroquine (HCQ) has shown some promise in the management of COVID 19. Minocycline, because of its anticytokine and other useful properties can be an ideal candidate for combining with...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2020.1832889

    authors: Gautam SS,Gautam CS,Garg VK,Singh H

    更新日期:2020-11-01 00:00:00

  • Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.

    abstract::Introduction: In September of 2018, the United States Federal Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) for advanced cutaneous squamous cell carcinoma (CSCC). Cemiplimab is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1). Cemiplimab blocks T-cell ina...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2019.1665026

    authors: Ahmed SR,Petersen E,Patel R,Migden MR

    更新日期:2019-10-01 00:00:00

  • The impact of molecular targets in cancer drug development: major hurdles and future strategies.

    abstract::The last decades were characterized by enormous technological advances resulting in a better understanding of disease pathologies and improvement of treatment strategies. The development of targeted drugs, whose beginning can be traced back to Paul Ehrlich's theory of the 'magic bullet' approximately 100 years ago, is...

    journal_title:Expert review of clinical pharmacology

    pub_type: 历史文章,杂志文章

    doi:10.1586/ecp.12.71

    authors: Hebar A,Valent P,Selzer E

    更新日期:2013-01-01 00:00:00

  • Three-month paliperidone palmitate - a new treatment option for schizophrenia.

    abstract:INTRODUCTION:Long-acting injectable antipsychotics (LAIAs) were introduced to improve treatment adherence and tolerability of oral formulations. After risperidone was introduced as the first long-acting injectable second-generation antipsychotic, during the last five years olanzapine pamoate, once-monthly paliperidone ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2016.1191945

    authors: Bernardo M,Bioque M

    更新日期:2016-07-01 00:00:00